Expand CRBP Menu
CRBP MENU

CRBP Latest Press Releases

-- December 11, 2025 --

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss Globe Newswire 7:00 AM

-- December 10, 2025 --

Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 Globe Newswire 4:01 PM

-- November 12, 2025 --

Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Globe Newswire 8:00 AM

-- October 31, 2025 --

Corbus Pharmaceuticals Announces Pricing of Public Offering Globe Newswire 2:40 AM

-- October 30, 2025 --

Corbus Pharmaceuticals Announces Proposed Public Offering Globe Newswire 4:31 PM

-- October 18, 2025 --

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25 Globe Newswire 3:00 AM

-- October 14, 2025 --

Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025 Globe Newswire 8:00 AM

-- October 7, 2025 --

Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium Globe Newswire 8:00 AM

-- September 22, 2025 --

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025 Globe Newswire 8:00 AM

-- September 16, 2025 --

FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma Globe Newswire 8:00 AM

-- August 5, 2025 --

Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Globe Newswire 8:00 AM

-- July 30, 2025 --

Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes